|
Obesity
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Erythrocyte acid phosphatase (ACP locus 1), also known as low-molecular-weight protein tyrosine phosphatase, has previously been associated to glycemia, dyslipidemia, and obesity.
|
19570551 |
2009 |
|
Congenital Abnormality
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The Cardiff survey did show a significant relationship between ACP-1 genotypes and the presence or absence of congenital abnormalities, but since this was largely attributable to an excess of ACP-1 CA individuals with abnormalities, a category with a small expected value, further data are required to confirm the validity of this observation.
|
3208680 |
1989 |
|
Cardiomyopathy, Dilated
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Cardiac-specific deletion of Ndufab1 in mice caused defective bioenergetics and elevated ROS levels, leading to progressive dilated cardiomyopathy and eventual heart failure and sudden death.
|
31366990 |
2019 |
|
Coronary Arteriosclerosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
p53 codon 72 polymorphism and coronary artery disease: evidence of interaction with ACP₁.
|
23197232 |
2012 |
|
Coronary heart disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
p53 codon 72 polymorphism and coronary artery disease: evidence of interaction with ACP₁.
|
23197232 |
2012 |
|
Favism
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Association between ACP(1) genetic polymorphism and favism.
|
21644204 |
2011 |
|
Hemolytic reaction
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
An association between favism (a hemolytic reaction to consumption of fava beans), glucose-6-phosphate dehydrogenase deficiency (G6PD(-)) and acid phosphatase locus 1 (ACP(1)) phenotypes has been reported; the frequency of carriers of the p(a) and p(c) ACP(1) alleles was found to be significantly higher in G6PD(-) individuals showing favism than in the general population.
|
21644204 |
2011 |
|
Actinic cheilitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Strong associations between alcoholic cirrhosis and alpha-1-antitrypsin PI*Z allele, haptoglobin HP*1 allele and acid phosphatase ACP AC phenotype were observed.
|
1512005 |
1992 |
|
Endometrial Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In this article, the authors have studied the relationship between ACP(1) genotype and grade in colon and endometrium cancers.
|
22692348 |
2012 |
|
Hereditary Nonpolyposis Colorectal Cancer
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Because both beta-catenin and ACP gene mutations have recently been shown to activate the same signaling pathway, we analyzed beta-catenin mutation in HNPCC tumors.
|
10493496 |
1999 |
|
Coronary Artery Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
p53 codon 72 polymorphism and coronary artery disease: evidence of interaction with ACP₁.
|
23197232 |
2012 |
|
Deficiency of glucose-6-phosphate dehydrogenase
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
An association between favism (a hemolytic reaction to consumption of fava beans), glucose-6-phosphate dehydrogenase deficiency (G6PD(-)) and acid phosphatase locus 1 (ACP(1)) phenotypes has been reported; the frequency of carriers of the p(a) and p(c) ACP(1) alleles was found to be significantly higher in G6PD(-) individuals showing favism than in the general population.
|
21644204 |
2011 |
|
Tuberculosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
Chemical synthesis and in silico molecular modeling of novel pyrrolyl benzohydrazide derivatives: Their biological evaluation against enoyl ACP reductase (InhA) and Mycobacterium tuberculosis.
|
28961440 |
2017 |
|
Tuberculosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
The pharmacophore features were then filtered by Surflex-dock study using enoyl ACP reductase from M. tuberculosis.
|
27889632 |
2017 |
|
Tuberculosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
The site of action of isoniazid, used in the treatment of tuberculosis for 50 years, and the consumer antimicrobial agent triclosan were revealed recently to be the enoyl-ACP reductase of the type II FAS.
|
11591436 |
2001 |
|
Tuberculosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.
|
16842188 |
2006 |
|
Tuberculosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
The pentacyano(isoniazid)ferrate(II) compound, named IQG-607, inhibits the enzyme 2-trans-enoyl-ACP(CoA) reductase from M. tuberculosis, a key component in the FASII system.
|
29281707 |
2017 |
|
Ataxic cerebral palsy
|
0.040 |
Biomarker
|
disease |
BEFREE |
In the absence of FXN, the NFS1-ISD11-ACP (SDA) complex was reportedly inhibited by binding of recombinant ISCU.
|
30031876 |
2018 |
|
Ataxic cerebral palsy
|
0.040 |
Biomarker
|
disease |
BEFREE |
Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.
|
16842188 |
2006 |
|
Ataxic cerebral palsy
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this study, we have investigated the influence of the quaternary structure of 2-trans-enoyl-ACP (CoA) reductase or InhA, from Mycobacterium tuberculosis, to its flexibility.
|
31548581 |
2019 |
|
Adamantinous Craniopharyngioma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In the absence of FXN, the NFS1-ISD11-ACP (SDA) complex was reportedly inhibited by binding of recombinant ISCU.
|
30031876 |
2018 |
|
Adamantinous Craniopharyngioma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.
|
16842188 |
2006 |
|
Adamantinous Craniopharyngioma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this study, we have investigated the influence of the quaternary structure of 2-trans-enoyl-ACP (CoA) reductase or InhA, from Mycobacterium tuberculosis, to its flexibility.
|
31548581 |
2019 |
|
Presenile dementia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Relative to white persons with dementia, African American persons with dementia were reported to have a lower preference for comfort care (81% vs. 58%) and lower rates of completion of legal ACP (89% vs. 73%).
|
31309906 |
2019 |
|
Presenile dementia
|
0.030 |
Biomarker
|
disease |
BEFREE |
We therefore aimed to further explore barriers and facilitators for ACP with community-dwelling people with dementia.
|
30115008 |
2018 |